Molecular insights company Foundation Medicine Inc announced on Friday that it has received approval from the US Food and Drug Administration (FDA) for FoundationOneLiquid CDx as a companion diagnostic to identify patients who would benefit from treatment with Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant.
On Thursday, biotechnology company Genentech, part of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), said that the FDA had approved Itovebi, in combination with palbociclib and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer following recurrence on or after completing adjuvant endocrine therapy.
Approximately 70% of all breast cancers are hormone-receptor positive, HER2-negative. PIK3CA is the most commonly mutated gene in this form of breast cancer, found in approximately 40% of patients.
With this approval, Foundation Medicine now has seven companion diagnostic indications for breast cancer.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial